



T1D EXCHANGE AND LOCEMIA SOLUTIONS TO PRESENT AT PARTNERING FOR CURES

November 14, 2014 - T1D Exchange will join Locemia Solutions to highlight a research collaboration at the 6th annual [Partnering for Cures](#), November 16-18 in New York City. Convened by [FasterCures](#), the Washington, D.C.-based center of the Milken Institute, the conference will bring together nearly 1,000 medical research leaders, investors and decision-makers to forge the collaborations needed to speed and improve outcomes-driven R&D.

Featuring senior executives from both organizations, the joint presentation from T1D Exchange and Locemia Solutions will showcase how the collaboration facilitated a number of key steps in the R&D process for a new drug delivery system. This included partnership through the development of study protocols for FDA review, patient recruitment for clinical trials and gathering patient feedback through a survey of the T1D Exchange online patient community, [Glu](#). Locemia Solution's experience highlighted how working with T1D Exchange can connect organizations with patients and healthcare providers at the earliest stages of the development process, help to mitigate barriers and inefficiencies for clinical and translational research and, ultimately, help improve outcomes for people living with type 1 diabetes.

"Thanks to support from the Helmsley Trust and the tremendous network established by the T1D Exchange, we've had the good fortune of collaborating with a range of stakeholders, including people with diabetes and healthcare providers, to accelerate the development of a product to address an important unmet medical need. Our team at Locemia is truly privileged to be involved in this exciting partnership," said Dr. Claude Piché, President & CEO of Locemia Solutions.

Partnering for Cures is designed to facilitate informed investments and cultivate relationships, adapting the outcomes-oriented approach of investor conferences, and building on the networking opportunities at industry partnering meetings. In addition to innovator presentations, it also features [panels](#) that spotlight solutions to long-standing challenges in medical research.

Locemia Solutions is one of [30 innovators](#) presenting their cross-sector research collaboration to potential partners and funders at the conference. Selected through a competitive proposal process, each partnership is aimed at reducing the time and cost of getting new medical solutions from discovery to patients.

"These collaborations address some of the thorniest issues in medical research using models that can be scaled and translated across diseases," said FasterCures' Executive Director Margaret Anderson. "From re-imagining clinical trial infrastructure to improving

and expanding data sharing, to creating the tools and resources needed to translate basic science into cures, they are accelerating the path from lab to market for novel – and needed – therapies.”

For more information and to register for the conference, go to www.partneringforcures.org

###

About Locemia Solutions

Locemia Solutions is a privately held, specialty pharmaceutical company located in Montreal, Canada. The company is focused exclusively on development efforts to make hypoglycemia rescue simple.

About T1D Exchange

T1D Exchange, the first program of [Unitio](#), was founded on the premise that finding faster, better therapies for type 1 diabetes (T1D) requires a research model as multi-faceted as the disease itself. T1D Exchange acts as a convener of the thousands of people working to improve patient outcomes already—by connecting them to one another and to the patient community at large. Drawing on decades of research and data that have come before, T1D Exchange aims to be the translational engine that enables the entire T1D ecosystem to collaborate in truly novel ways via the integration of a Clinic Network, Clinic Registry, Biobank, and the online patient/caregiver community, [Glu](#).

About the Leona M. and Harry B. Helmsley Charitable Trust

The Helmsley Charitable Trust aspires to improve lives by supporting effective nonprofits in health, place-based initiatives, and education and human services. Since 2008, when the Trust began its active grant making, it has committed more than \$1 billion. The Helmsley Type 1 Diabetes Program is the largest private funder of T1D-related research, treatment and support programs.